AER 1508343 is a spontaneous case, was received on 12/Dec/2014, from a physician and concerns a 44 year old 
female patient who developed progressive multifocal leukoencephalopathy while being treated with rituximab 
(Mabthera).
No medical history, concurrent conditions, concomitant medications or past drugs were reported.
On an unspecified date, the patient started therapy with rituximab (dosage regimen not provided) for non hodgkins 
lymphoma. Later, she developed progressive multifocal leukoencephalopathy. It was reported that recently, the 
rituximab level was at a very high level. The neurologist proposed of removing rituximab from the blood by plasma 
paresis and the John Cunningham viral load was also high. In Sep/2014, she received the last rituximab 
application. Three plasma pareses with a plasma exchange of each three liters were performed. rituximab level 
was measured, however the result was not provided.
Print Time: 26-MAY-2016 01:56 PM If a field is blank, there is no data for that field Page 253 of 675
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
At the time of this report, progressive multifocal leukoencephalopathy was persisting. It was unknown whether 
therapy with rituximab was ongoing.
The physician did not report the causal relationship of progressive multifocal leukoencephalopathy with rituximab.
The company assessed the progressive multifocal leukoencephalopathy as medically significant. 
No further information was provided.
Additonal information was received on 02/Feb/2015. The following information were added to the case: Reporter 
comment added (Three plasma pareses with a plasma exchange of each three liters were performed. rituximab 
level was measured, however the result was not provided).